- Home
- BRSP vs PHAT Comparison
BRSP vs PHAT Comparison
Compare BRSP & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- PHAT
- Stock Information
- Founded
- BRSP 2017
- PHAT 2018
- Country
- BRSP United States
- PHAT United States
- Employees
- BRSP N/A
- PHAT N/A
- Industry
- BRSP Real Estate Investment Trusts
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- BRSP Real Estate
- PHAT Health Care
- Exchange
- BRSP Nasdaq
- PHAT Nasdaq
- Market Cap
- BRSP 665.4M
- PHAT 640.9M
- IPO Year
- BRSP 2018
- PHAT 2019
- Fundamental
- Price
- BRSP $5.55
- PHAT $10.24
- Analyst Decision
- BRSP Buy
- PHAT Strong Buy
- Analyst Count
- BRSP 4
- PHAT 5
- Target Price
- BRSP $6.38
- PHAT $16.40
- AVG Volume (30 Days)
- BRSP 821.1K
- PHAT 1.1M
- Earning Date
- BRSP 07-29-2025
- PHAT 08-07-2025
- Dividend Yield
- BRSP 11.55%
- PHAT N/A
- EPS Growth
- BRSP N/A
- PHAT N/A
- EPS
- BRSP N/A
- PHAT N/A
- Revenue
- BRSP $335,107,000.00
- PHAT $114,039,000.00
- Revenue This Year
- BRSP N/A
- PHAT $194.40
- Revenue Next Year
- BRSP $9.97
- PHAT $103.23
- P/E Ratio
- BRSP N/A
- PHAT N/A
- Revenue Growth
- BRSP N/A
- PHAT 1049.82
- 52 Week Low
- BRSP $4.16
- PHAT $2.21
- 52 Week High
- BRSP $6.45
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- BRSP 67.74
- PHAT 63.28
- Support Level
- BRSP $5.23
- PHAT $8.03
- Resistance Level
- BRSP $5.60
- PHAT $11.19
- Average True Range (ATR)
- BRSP 0.15
- PHAT 0.63
- MACD
- BRSP 0.04
- PHAT 0.16
- Stochastic Oscillator
- BRSP 92.54
- PHAT 69.98
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.